Investigational Site Number :7240007

Madrid 28046

3 studies enrolling now · 11 studies all time

What they study most

Asthma, Breast Cancer, Celiac Disease, Chronic Obstructive Pulmonary Disease, Coeliac Disease, Focal Segmental Glomerulosclerosis, Glomerulonephritis Minimal Lesion, Immune Thrombocytopenia, Neoplasm, Neoplasm Malignant, Neurodermatitis, Rheumatoid Arthritis

Studies at this site

A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change Disease — Recruiting now
A Study to Investigate Efficacy and Safety of Teplizumab Compared With Placebo in Participants 1 to 25 Years of Age With Stage 3 Type 1 Diabetes — Recruiting now
Study to Evaluate the Efficacy and Safety of Oral Rilzabrutinib in Adults With Immune Thrombocytopenia (ITP) Who Failed First-line Treatment — Recruiting now
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma — Running, not enrolling
First-in-human Single Agent Study of SAR442257 in RRMM and RR-NHL — Completed
A Study to Investigate Long-term Safety and Tolerability of Itepekimab in Participants With COPD — Running, not enrolling
A Phase 2a/b Study of the Efficacy and Safety of Subcutaneous Amlitelimab in Adults With Nonresponsive Celiac Disease — Running, not enrolling
Phase 1/2 Study of Amcenestrant (SAR439859) Single Agent and in Combination With Other Anti-cancer Therapies in Postmenopausal Women With Estrogen Receptor Positive Advanced Breast Cancer — Stopped early
Study of Dupilumab for the Treatment of Patients With Prurigo Nodularis, Inadequately Controlled on Topical Prescription Therapies or When Those Therapies Are Not Advisable (PRIME2) — Completed
A Study to Evaluate SAR441566 Efficacy and Safety in Adults With Rheumatoid Arthritis — Completed
Safety, Preliminary Efficacy and PK of Isatuximab (SAR650984) Alone or in Combination With Atezolizumab in Patients With Advanced Malignancies — Stopped early